- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04629547
Sleep Trial to Prevent Alzheimer's Disease (SToP-AD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Cristina Toedebusch, BS
- Phone Number: 3147470646
- Email: toedebuschc@wustl.edu
Study Contact Backup
- Name: Chloe Meehan, MA
- Phone Number: 3142730878
- Email: cmeehan@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Contact:
- Cristina Toedebusch, BS
- Phone Number: 314-747-0646
- Email: toedebuschc@wustl.edu
-
Principal Investigator:
- Brendan Lucey, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female.
- Any race or ethnicity.
- Participants must be age ≥65 years and able to sign informed consent.
- Global Clinical Dementia Rating (CDR) 0.
- Willing and able to undergo study procedures.
Exclusion Criteria:
- History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia
- Actigraphic sleep efficiency ≥85%.
- Abnormal movement of the non-dominant arm (would affect actigraphy data in unpredictable ways).
- STOP-Bang score ≥ 5.
- Untreated OSA with AHI ≥15 on home sleep test
Treated sleep apnea with PAP non-compliance
- PAP compliance is defined as >= 4 hours per night >70% of the nights
- Plasma A-beta and tau test with a plasma p-tau 217% ≤0.82
- Stroke.
- Chronic kidney disease defined as patients with markers of kidney damage or eGFR of < 60 ml/min/1.73m2.
- Hepatic impairment defined as AST and/or ALT > 2x upper limit of normal (normal limits AST: 11-47 IU/L, ALT: 6-53 IU/L).
- HIV/AIDS.
- Body mass index >35.
- History of substance abuse or alcoholism in the proceeding 6 months.
- History of regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded.
- History of presence of any clinically significant medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate.
Has any medical condition that, in the PI's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data. Potential medical conditions that will be exclusionary at the PI's discretion:
- Cardiovascular disease requiring medication except for controlled hypertension.
- Pulmonary disease.
- Type I diabetes.
- Neurologic or psychiatric disorder requiring medication.
- Tobacco use.
- Use of sedating medications.
- Use of medications that interact with suvorexant (if cannot be discontinued)
- Abnormal safety labs
- History of current suicidal ideations.
- Currently pregnant or breast-feeding.
- In the opinion of the PI, the participant should be excluded due to an abnormal physical examination.
- Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.
- Must not participate in another drug or device study prior to the end of this study participation.
Exclusion criteria for optional lumbar punctures
-• Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Poor sleep treatment group
100 participants will be randomized to take suvorexant 20mg daily at h.s. for two years
|
Suvorexant 20mg will be taken nightly for 24 months.
Other Names:
|
Placebo Comparator: Poor sleep control grop
100 participants will be randomized to take placebo daily at h.s. for two years.
|
Placebo will be taken nightly for 24 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Amyloid-β accumulation detected by plasma pT217/T217 compared to placebo
Time Frame: 24 months
|
Blood collection
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in plasma Amyloid-β compared to placebo
Time Frame: 24 months
|
Blood collection
|
24 months
|
Change in CSF Amyloid-β compared to placebo
Time Frame: 24 months
|
Cerebrospinal fluid collection
|
24 months
|
Change in plasma tau compared to placebo
Time Frame: 24 months
|
Blood collection
|
24 months
|
Change in CSF tau compared to placebo
Time Frame: 24 months
|
Cerebrospinal fluid collection
|
24 months
|
Change in plasma p-tau compared to placebo
Time Frame: 24 months
|
Blood collection
|
24 months
|
Change in CSF p-tau compared to placebo
Time Frame: 24 months
|
Cerebrospinal fluid collection
|
24 months
|
Change in cognitive performance compared to placebo
Time Frame: 24 months
|
Measured by a cognitive composite consisting of the Digit Symbol Substitution Test, Animal Naming, Trails B and the Free and Cued Selective Reminding Test.
Each test will be z-scored and then averaged together to make the composite.
|
24 months
|
Change in transcriptomics compared to placebo
Time Frame: 24 months
|
blood and optional CSF collection
|
24 months
|
Change in metabolomics compared to placebo
Time Frame: 24 months
|
blood and optional CSF collection
|
24 months
|
Change in proteomics compared to placebo
Time Frame: 24 months
|
blood and optional CSF collection
|
24 months
|
Change in gut microbiome compared to placebo
Time Frame: 214 months
|
optional stool sample collection
|
214 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Brendan Lucey, MD, Washington Univeristy School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Hypnotics and Sedatives
- Sleep Aids, Pharmaceutical
- Orexin Receptor Antagonists
- Suvorexant
Other Study ID Numbers
- 2020008007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep
-
University of Wisconsin, MadisonPhilips HealthcareCompletedSleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization
-
Brain Electrophysiology Laboratory CompanyRecruiting
-
University GhentEuropean CommissionEnrolling by invitation
-
Northumbria UniversityCompletedSleep | Mood | Poor Quality Sleep | Good Sleep HabitUnited Kingdom
-
Baylor College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruiting
-
Brain Electrophysiology Laboratory CompanyCompletedSleep | Sleep HygieneUnited States
-
Koko Home, Inc.Stanford UniversityRecruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Sleep HygieneUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, Wisconsin; Divine Savior...Active, not recruitingSleep | Sleep HygieneUnited States
-
Aretaieion University HospitalRecruitingSleep Disorder | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Surgery | Anesthesia | Sleep Fragmentation | Sleep Disorders, Circadian RhythmGreece
-
ResMedCRI-The Clinical Research Institute GmbH; University Hospital RegensburgCompletedObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep Apnea | Complex Sleep ApneaSwitzerland, Spain, Denmark, Portugal, France, Germany
Clinical Trials on Suvorexant 20 mg
-
The University of Texas Health Science Center,...Recruiting
-
Mclean HospitalRecruiting
-
Henry Ford Health SystemCompleted
-
Duke UniversityMerck Sharp & Dohme LLCRecruitingDelirium in Old AgeUnited States
-
The Florey Institute of Neuroscience and Mental...Melbourne Health; St Vincent's Hospital MelbourneTerminatedInsomnia | Alcohol Use DisorderAustralia
-
Milton S. Hershey Medical CenterCompletedSleep Disturbance | Craving | Cortisol; HypersecretionUnited States
-
Vanda PharmaceuticalsCompletedNon-24-Hour-Sleep-Wake Disorder
-
Beth Israel Deaconess Medical CenterMerck Sharp & Dohme LLCRecruitingInsomnia | Sleep Initiation and Maintenance Disorders | Postoperative Delirium | Sleep FragmentationUnited States
-
The Scripps Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Use Disorder (AUD)United States
-
Eisai Co., Ltd.Completed